IL6 and COVID-19: Gordon et al. [29] conducted a Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP; NCT02735707) for evaluating the use of anti-IL-6 mAbs, i.e., TCZ and sarilumab in the treatment of critical cases of COVID-19.